Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders.
about
Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? YesIs ADAMTS-13 deficiency specific for thrombotic thrombocytopenic purpura? NoPlasma from patients with thrombotic thrombocytopenic purpura induces activation of human monocytes and polymorphonuclear neutrophils.Diagnosis of thrombotic thrombocytopenic purpura based on modulation by patient plasma of normal platelet adhesion under flow condition.A perspective on the measurement of ADAMTS13 in thrombotic thrombocytopaenic purpura.Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods.The activity of the von Willebrand factor cleaving protease ADAMTS-13 in newborn infants.Nine years of cascade filtration for thrombotic thrombocytopenic purpura.Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet.Thrombotic thrombocytopenic purpura and its diagnosis.The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura: reconsideration of treatment with cryopoor plasma.Thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus.Bench-to-bedside review: thrombocytopenia-associated multiple organ failure--a newly appreciated syndrome in the critically illIntravenous immunoglobulin as an adjunct to plasma exchange for the treatment of chronic thrombotic thrombocytopenic purpura.Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failureThrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patientsElevated procalcitonin and C-reactive protein as potential biomarkers of sepsis in a subpopulation of thrombotic microangiopathy patientsRituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura--haemolytic uraemic syndromeRetrospective review of 25 cases of thrombotic thrombocytopenic purpura in Pakistan.Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura.Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.von Willebrand factor: more than a regulator of hemostasis and thrombosis.Deficiency of ADAMTS-13 in pediatric patients with severe sepsis and impact on in-hospital mortalityAlternate considerations for current concepts in ITP.Stability of relevant plasma protein activities in cryosupernatant plasma units during refrigerated storage for up to 5 days postthaw.Rebalanced hemostasis in patients with idiopathic thrombocytopenic purpura.VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP.How I treat refractory thrombotic thrombocytopenic purpura.Immune thrombocytopenic purpurae presenting with cortical vein thrombosis: is it rebalanced hemostasis?Thrombocytopenia in pregnancy with different diagnoses: Differential clinical features, treatments, and outcomes.Shwartzman phenomenon in a patient with active systemic lupus erythematosus preceding fatal disseminated intravascular coagulation.Use of cellular and plasma apheresis in the critically ill patient: Part II: Clinical indications and applications.IL-1β down-regulates ADAMTS-13 mRNA expression in cells of the central nervous system.Low ADAMTS-13 activity during hemorrhagic events with disseminated intravascular coagulation.Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients.Levels of von Willebrand factor-cleaving protease are normal in methylene blue-treated fresh-frozen plasma.Plasma ADAMTS-13 activity in proliferative lupus nephritis: a large cohort study from China.Thrombotic thrombocytopenic purpura
P2860
Q28188189-BF84327F-533D-4AFA-9175-FA0B8C5EA294Q28188198-50CA5E39-4943-4277-BC66-618E81276EBDQ33345792-5375DF89-2CFA-4190-A41C-3A81C79BA781Q33346565-BF2E6C0A-42E2-46FE-A973-79F1BE600EB5Q33347147-91ABA211-05EE-404D-84E7-7A6A676DE5E8Q33349688-4F0EFC42-10E2-449C-B9CA-C0F3078EA617Q33359816-4D90C0C8-0784-406B-9A61-22AA83C84DF9Q33361706-DC761B10-84EA-4D72-B83E-C1E39B8DA2C8Q33365640-08712A42-9CFE-4677-AF63-5ED45955A37DQ33366296-5AD3A88F-4C26-4AC1-913F-D2AEEF2FDAE7Q33369832-C58A7CA7-AD39-498D-9973-53F127427C73Q33369985-12C7B184-F62D-4952-9A34-02BC1F5E4C1BQ33373238-A8CDEB68-B6F2-4D5D-B05C-1B5D8CF2FF1EQ33376163-92D3159E-14EF-4334-A4B8-1D963E915519Q33381364-6E8598CE-3958-4CEC-8841-4BC1CD33187EQ33382221-A5403295-2A2E-4D83-BD12-4A4F71B38669Q33385335-D49CDAAC-B4BE-419D-894A-54B208E9B896Q33391086-D9706321-A3F8-43BD-96FF-58EC6BE6755BQ33399210-8DDACD81-7D9D-448D-9213-50EE0FC53B23Q33400631-CCE5294D-E20E-46FC-AF7D-6BEE84194A20Q33401403-0ABDAAF0-9C7D-41E2-9B23-A0B938702095Q33402792-18CC5B83-B23F-4E5B-A423-15B1ADD23ADFQ33406706-361FF36B-8C0A-4C9C-847B-EA0FC934B541Q33407813-72BED87F-D2ED-428D-8192-3CDD38E19079Q33407886-657D79C8-13AC-4267-95ED-9DBCA76DA28AQ33412708-CA4ED1F7-E164-4A2A-8F5B-4B9DBD577885Q33419324-D0D438B0-373C-4A91-A961-002C70CB182EQ33421268-F0EF0A27-7575-43F0-BDD5-FAF080D39557Q33427390-B6FC683B-1980-4F44-91A8-93A7B423CC9FQ33443791-7F26E7CD-174F-49A0-8BE8-0A7981580ACFQ33959460-CCC27044-57B2-4DF6-AE83-CA4F6F241850Q36108261-AC144597-3E7D-4EC3-939F-FCFF39BDC0D7Q39512224-D5389136-064C-4A3C-82F2-48F6E908A85AQ43839468-93E60942-D33D-4633-8D62-7889D87C9A16Q44763754-954B08DE-8AE8-42EB-8F88-DF881299100CQ50500906-0460763D-9185-45C9-B3AA-280218F06C61Q52759733-BAC6BEF9-4147-4504-8723-7CD090B5AF46Q57591162-E4C8B173-7EEB-447E-B326-30156D15BF1B
P2860
Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Decreased von Willebrand facto ...... th thrombocytopenic disorders.
@ast
Decreased von Willebrand facto ...... th thrombocytopenic disorders.
@en
Decreased von Willebrand facto ...... th thrombocytopenic disorders.
@nl
type
label
Decreased von Willebrand facto ...... th thrombocytopenic disorders.
@ast
Decreased von Willebrand facto ...... th thrombocytopenic disorders.
@en
Decreased von Willebrand facto ...... th thrombocytopenic disorders.
@nl
prefLabel
Decreased von Willebrand facto ...... th thrombocytopenic disorders.
@ast
Decreased von Willebrand facto ...... th thrombocytopenic disorders.
@en
Decreased von Willebrand facto ...... th thrombocytopenic disorders.
@nl
P2093
P356
P1433
P1476
Decreased von Willebrand facto ...... th thrombocytopenic disorders.
@en
P2093
P304
P356
10.1182/BLOOD.V98.6.1842
P407
P577
2001-09-01T00:00:00Z